NASDAQ:MLTX MoonLake Immunotherapeutics Q2 2026 Earnings Report $18.71 -1.17 (-5.89%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$19.11 +0.40 (+2.12%) As of 08:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast MoonLake Immunotherapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.90Beat/MissN/AOne Year Ago EPSN/AMoonLake Immunotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMoonLake Immunotherapeutics Announcement DetailsQuarterQ2 2026Date8/4/2026TimeBefore Market OpensConference Call DateWednesday, August 5, 2026Conference Call Time12:30PM ETConference Call ResourcesEarnings HistoryCompany Profile MoonLake Immunotherapeutics Earnings HeadlinesEquities Analysts Offer Predictions for MLTX Q2 EarningsJuly 24, 2026 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)July 22, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.July 29 at 1:00 AM | InvestorPlace (Ad)Moonlake Immunotherapeutics Share Price (MLTX.US)July 15, 2026 | lse.co.ukSLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff NearsJuly 12, 2026 | finance.yahoo.comMoonLake Immunotherapeutics Class AJuly 11, 2026 | edition.cnn.comSee More MoonLake Immunotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email. Email Address About MoonLake ImmunotherapeuticsMoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.View MoonLake Immunotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles These 3 Stocks Have Soared in 2026—Can They Keep Climbing?Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy StoryRambus: Another AI Phoenix Ready to Rise From the Ashes of CorrectionAmkor Sells Off After Earnings—Why Weak Guidance Isn't the Real StoryWestern Digital’s Earnings Will Test Whether Its AI Rally Has More RoomIs the Market Mispricing ServiceNow's AI Future?Whirlpool’s Report May Show How Frozen the Housing Market Really Is Upcoming Earnings Ferrari (7/30/2026)Air Products and Chemicals (7/30/2026)ArcelorMittal (7/30/2026)Vale (7/30/2026)Mastercard (7/30/2026)Apple (7/30/2026)ASE Technology (7/30/2026)Monolithic Power Systems (7/30/2026)CRH (7/30/2026)Quanta Services (7/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
